These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14667472)

  • 1. Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans.
    Walton K; Dorne JL; Renwick AG
    Food Chem Toxicol; 2004 Feb; 42(2):261-74. PubMed ID: 14667472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment.
    Dorne JL; Walton K; Renwick AG
    Food Chem Toxicol; 2004 Feb; 42(2):275-98. PubMed ID: 14667473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates.
    Walton K; Dorne JL; Renwick AG
    Food Chem Toxicol; 2001 Jul; 39(7):667-80. PubMed ID: 11397514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation.
    Walton K; Dorne JL; Renwick AG
    Food Chem Toxicol; 2001 Dec; 39(12):1175-90. PubMed ID: 11696391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts.
    Zu K; Pizzurro DM; Lewandowski TA; Goodman JE
    Regul Toxicol Pharmacol; 2017 Oct; 89():83-94. PubMed ID: 28720346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, variability and risk assessment.
    Dorne JL
    Toxicology; 2010 Feb; 268(3):156-64. PubMed ID: 19932147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of human pharmacokinetics - renal metabolic and excretion clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Nov; 59(11):1463-71. PubMed ID: 17976256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives.
    Tsunekawa Y; Hasegawa T; Nadai M; Takagi K; Nabeshima T
    J Pharm Pharmacol; 1992 Jul; 44(7):594-9. PubMed ID: 1357141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human.
    Timchalk C; Nolan RJ
    Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective.
    Gundert-Remy U; Sonich-Mullin C;
    Sci Total Environ; 2002 Apr; 288(1-2):3-11. PubMed ID: 12013545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnitude and mechanistic determinants of the interspecies toxicokinetic uncertainty factor for organic chemicals.
    Pelekis M; Krishnan K
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):264-71. PubMed ID: 15546680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principles and clinical application of assessing alterations in renal elimination pathways.
    Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
    Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boron tolerable intake: re-evaluation of toxicokinetics for data-derived uncertainty factors.
    Dourson M; Maier A; Meek B; Renwick A; Ohanian E; Poirier K
    Biol Trace Elem Res; 1998; 66(1-3):453-63. PubMed ID: 10050937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical-specific adjustment factors (inter-species toxicokinetics) to establish the ADI for steviol glycosides.
    Roberts A; Lynch B; Rogerson R; Renwick A; Kern H; Coffee M; Cuellar-Kingston N; Eapen A; Crincoli C; Pugh G; Bhusari S; Purkayastha S; Carakostas M
    Regul Toxicol Pharmacol; 2016 Aug; 79():91-102. PubMed ID: 27181453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal clearance-lipophilicity relationships of some organic acids in rabbits, rats and mice.
    Láznícek M
    J Pharm Pharmacol; 1992 Mar; 44(3):255-7. PubMed ID: 1354735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety factors and establishment of acceptable daily intakes.
    Renwick AG
    Food Addit Contam; 1991; 8(2):135-49. PubMed ID: 1868926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation.
    Dorne JL
    Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saturable pharmacokinetics in the renal excretion of drugs.
    van Ginneken CA; Russel FG
    Clin Pharmacokinet; 1989 Jan; 16(1):38-54. PubMed ID: 2650954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data-derived safety factors for the evaluation of food additives and environmental contaminants.
    Renwick AG
    Food Addit Contam; 1993; 10(3):275-305. PubMed ID: 8359312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.